{
    "clinical_study": {
        "@rank": "16526", 
        "arm_group": {
            "arm_group_label": "LY2835219", 
            "arm_group_type": "Experimental", 
            "description": "200 milligram (mg) LY2835219 administered orally every 12 hours on days 1 through 28 of a 28-day cycle"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to estimate the disease control rate with LY2835219 for\n      relapsed or refractory mantle cell lymphoma."
        }, 
        "brief_title": "Study of LY2835219 for Mantle Cell Lymphoma", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Mantle Cell Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Mantle-Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have a diagnosis of relapsed or refractory Mantle Cell Lymphoma (MCL) according to\n             the World Health Organization (WHO) classification that has relapsed after, or been\n             refractory to, available standard treatments. However, participants who are\n             intolerant of, or unable to receive a standard treatment are not required to have MCL\n             that has relapsed after, or been refractory to, that specific standard treatment.\n             Pathology must be reviewed and confirmed at the investigational site where\n             participant is entered prior to enrollment\n\n          -  Have disease that is assessable according to the Response Criteria for Non- Hodgkin's\n             Lymphomas\n\n          -  Have given written informed consent prior to any study-specific procedures\n\n          -  Have adequate organ function including:\n\n               -  Hematologic: Absolute neutrophil count (ANC) \u22651.5 x 10^9/Liter (L), platelets\n                  \u226575 x 10^9/L, and hemoglobin \u22658 grams per deciliter (g/dL)\n\n               -  Hepatic: Bilirubin \u22641.5 times upper limits of normal (ULN) and alanine\n                  aminotransferase (ALT) \u22643.0 times ULN\n\n               -  Renal: Estimated creatinine clearance \u226550 milliliter per minute (ml/min)\n\n          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or\n             2\n\n          -  Have discontinued all previous therapies for cancer (including chemotherapy,\n             radiotherapy, immunotherapy, and investigational therapy) for at least 21 days for\n             myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving\n             study drug, and recovered from the acute effects of therapy (treatment-related\n             toxicity resolved to baseline) except for residual alopecia\n\n          -  Are willing to make themselves available for the duration of the study and to follow\n             study procedures\n\n          -  Are amenable to compliance with protocol schedules and testing\n\n          -  Males and females with reproductive potential must agree to use medically approved\n             contraceptive precautions during the trial and for 3 months following the last dose\n             of study drug\n\n          -  Females with child-bearing potential must have a negative serum pregnancy test within\n             14 days of the first dose of study drug\n\n          -  Have a life expectancy of \u226512 weeks\n\n          -  Are able to swallow capsules\n\n        Exclusion Criteria:\n\n          -  Are currently enrolled in, or discontinued within 14 or 21 days of the initial dose\n             of study drug for a nonmyelosuppressive or myelosuppressive agent, respectively, a\n             clinical trial involving an investigational product or non-approved use of a drug or\n             device other than the study drug used in this study, or concurrently enrolled in any\n             other type of medical research judged not to be scientifically or medically\n             compatible with this study\n\n          -  Have serious preexisting medical conditions that, in the judgment of the\n             investigator, would preclude participation in this study (for example, pneumonia,\n             inflammatory bowel disease, history of major surgical resection involving the stomach\n             or small bowel)\n\n          -  Have symptomatic metastasis to the central nervous system (CNS). Participants may\n             have CNS metastasis that is radiographically or clinically stable for at least 14\n             days prior to receiving study drug, regardless of whether they are receiving\n             corticosteroids\n\n          -  Have received an autologous or allogeneic stem-cell transplant within 75 days of the\n             initial dose of study drug. In addition, recipients of an allogenic stemcell\n             transplant must have discontinued immunosuppressive therapy at least 14 days before\n             study drug administration with no more than Grade 1 acute graft versus-host disease\n             on Day 1 of Cycle 1\n\n          -  Females who are pregnant or lactating\n\n          -  Have active bacterial, fungal, and/or known viral infection (for example, human\n             immunodeficiency virus [HIV] antibodies, hepatitis B surface antigen [HBSAg], or\n             hepatitis C antibodies). Screening is not required for enrollment\n\n          -  Have a baseline electrocardiogram (ECG) with any of the following findings:\n             ventricular tachycardia, ventricular fibrillation, abnormal QTcB (defined as \u2265450\n             milliseconds for males and \u2265470 milliseconds for females), or evidence of acute\n             myocardial ischemia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01739309", 
            "org_study_id": "13269", 
            "secondary_id": [
                "I3Y-MC-JPBB", 
                "2012-003614-14"
            ]
        }, 
        "intervention": {
            "arm_group_label": "LY2835219", 
            "description": "Administered orally", 
            "intervention_name": "LY2835219", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Non- Hodgkins Lymphoma", 
        "lastchanged_date": "May 16, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "zip": "59037"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75475"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Pessac", 
                        "country": "France", 
                        "zip": "33604"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France", 
                        "zip": "35033"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "G\u00f6ttingen", 
                        "country": "Germany", 
                        "zip": "37075"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Homburg", 
                        "country": "Germany", 
                        "zip": "66421"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Kassel", 
                        "country": "Germany", 
                        "zip": "34125"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Mainz", 
                        "country": "Germany", 
                        "zip": "55131"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "N\u00fcrnberg", 
                        "country": "Germany", 
                        "zip": "90419"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Ulm", 
                        "country": "Germany", 
                        "zip": "89081"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Germany"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 2 Study of a CDK4/6 Inhibitor for Patients With Relapsed or Refractory Mantle Cell Lymphoma", 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Proportion of Participants who Achieve Best Overall Disease Response of Complete Response (CR), Complete Response unconfirmed (CRu), Partial Response (PR) or Stable Disease (SD)", 
            "safety_issue": "No", 
            "time_frame": "Baseline until Disease Progression or Start of New Anticancer Therapy (Estimated up to 28 Months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01739309"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of Participants who Achieve Best Overall Disease Response of CR, CRu or PR", 
                "safety_issue": "No", 
                "time_frame": "Baseline until Disease Progression (Estimated up to 28 Months)"
            }, 
            {
                "measure": "Duration of Response", 
                "safety_issue": "No", 
                "time_frame": "Date of CR, CRu or PR until Disease Progression or Death Due to Any Cause (Estimated up to 28 Months)"
            }, 
            {
                "measure": "Progression-Free Survival", 
                "safety_issue": "No", 
                "time_frame": "Date of First Dose until Diease Progression or Death Due to Any Cause (Estimated up to 28 Months)"
            }, 
            {
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "Date of First Dose until Death Due to Any Cause (Estimated up to 28 Months)"
            }, 
            {
                "measure": "Change from Baseline in Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Total Score and Subscales", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 30 Day Post Therapy (Estimated up to 28 Months)"
            }, 
            {
                "measure": "Pharmacokinetics (PK):  Maximum Concentration (Cmax) of LY2835219 and its metabolites", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 10 Hours Postdose"
            }, 
            {
                "measure": "PK - Area Under the Concentration-Time Curve (AUC) of LY283219 and its metabolites", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 10 Hours Postdose"
            }, 
            {
                "measure": "PK - Terminal Half Life (T 1/2) of LY2835219 and its metabolites", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 10 hours Postdose"
            }, 
            {
                "measure": "PK: Volume of Distribution (Vd) of LY2835219 and its metabolites", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 10 Hours Postdose"
            }, 
            {
                "measure": "PK: Clearance (CL) of LY2835219 and its metabolites", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 10 Hours Postdose"
            }, 
            {
                "measure": "Event-Free Survival", 
                "safety_issue": "No", 
                "time_frame": "Baseline until Disease Progression or Death Due to Any Cause (Estimated up to 28 Months)"
            }, 
            {
                "measure": "Time to Disease Progression", 
                "safety_issue": "No", 
                "time_frame": "Baseline until Disease Progression (Estimated up to 28 Months)"
            }, 
            {
                "measure": "Disease-Free Survival", 
                "safety_issue": "No", 
                "time_frame": "Baseline until Disease Progression (Estimated up to 28 Months)"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}